The CheckMate 214 trial led to the first approved ICI regimen in the frontline setting for metastatic ccRCC by combining nivolumab with the CTLA-4 inhibitor ipilimumab4. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.